Benjamin Faurie1, Géraud Souteyrand2, Patrick Staat3, Matthieu Godin4, Christophe Caussin5, Eric Van Belle6, Lionel Mangin7, Pierre Meyer8, Nicolas Dumonteil9, Mohamed Abdellaoui10, Jacques Monségu10, Isabelle Durand-Zaleski11, Thierry Lefèvre12. 1. Institut Cardiovasculaire, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Cardiology Department, Médipole HP Lyon-Villeurbane, Villeurbane, France. Electronic address: faurieb@gmail.com. 2. Cardiology Department, Centre Hospitalier Universitaire Gabriel-Montpied, Clermont-Ferrand, France. 3. Cardiology Department, Médipole HP Lyon-Villeurbane, Villeurbane, France. 4. Cardiology Department, Clinique Saint Hilaire, Rouen, France. 5. Cardiology Department, Institut Mutualiste Montsouris, Paris, France. 6. Département de cardiologie, Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France. 7. Cardiology Department, Centre Hospitalier Annecy Genevois, Epagny, France. 8. Cardiology Department, Institut Arnault Tzanck, Saint-Laurent-du-Var, France. 9. Cardiology Department, Clinique Pasteur, Toulouse, France. 10. Institut Cardiovasculaire, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France; Cardiology Department, Médipole HP Lyon-Villeurbane, Villeurbane, France. 11. Cardiology Department, URC-Eco Île de France, Hôpital de l'Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France. 12. Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France.
Abstract
OBJECTIVES: This study investigated whether left ventricular (LV) stimulation via a guidewire-reduced procedure duration while maintaining efficacy and safety compared with standard right ventricular (RV) stimulation. BACKGROUND:Rapid ventricular pacing is necessary to ensure cardiac standstill during transcatheter aortic valve replacement (TAVR). METHODS: This is a prospective, multicenter, single-blinded, superiority, randomized controlled trial. Patients undergoing transfemoral TAVR with a SAPIEN valve (Edwards Lifesciences, Irvine, California) were allocated to LV or RV stimulation. The primary endpoint was procedure duration. Secondary endpoints included efficacy, safety, and cost at 30 days. RESULTS:Between May 2017 and May 2018, 307 patients were randomized, but 4 were excluded because they did not receive the intended treatment: 303 patients were analyzed in the LV (n = 151) or RV (n = 152) stimulation groups. Mean procedure duration was significantly shorter in the LV stimulation group (48.4 ± 16.9 min vs. 55.6 ± 26.9 min; p = 0.0013), with a difference of -0.12 (95% confidence interval: -0.20 to -0.05) in the log-transformed procedure duration (p = 0.0012). Effective stimulation was similar in the LV and RV stimulation groups: 124 (84.9%) versus 128 (87.1%) (p = 0.60). Safety of stimulation was also similar in the LV and RV stimulation groups: procedural success occurred in 151 (100%) versus 151 (99.3%) patients (p = 0.99); 30-day MACE-TAVR (major adverse cardiovascular event-transcatheter aortic valve replacement) occurred in 21 (13.9%) versus 26 (17.1%) patients (p = 0.44); fluoroscopy time (min) was lower in the LV stimulation group (13.48 ± 5.98 vs. 14.60 ± 5.59; p = 0.02), as was cost (€18,807 ± 1,318 vs. €19,437 ± 2,318; p = 0.001). CONCLUSIONS: Compared with RV stimulation, LV stimulation during TAVR was associated with significantly reduced procedure duration, fluoroscopy time, and cost, with similar efficacy and safety. (Direct Left Ventricular Rapid Pacing Via the Valve Delivery Guide-wire in TAVR [EASY TAVI]; NCT02781896).
RCT Entities:
OBJECTIVES: This study investigated whether left ventricular (LV) stimulation via a guidewire-reduced procedure duration while maintaining efficacy and safety compared with standard right ventricular (RV) stimulation. BACKGROUND: Rapid ventricular pacing is necessary to ensure cardiac standstill during transcatheter aortic valve replacement (TAVR). METHODS: This is a prospective, multicenter, single-blinded, superiority, randomized controlled trial. Patients undergoing transfemoral TAVR with a SAPIEN valve (Edwards Lifesciences, Irvine, California) were allocated to LV or RV stimulation. The primary endpoint was procedure duration. Secondary endpoints included efficacy, safety, and cost at 30 days. RESULTS: Between May 2017 and May 2018, 307 patients were randomized, but 4 were excluded because they did not receive the intended treatment: 303 patients were analyzed in the LV (n = 151) or RV (n = 152) stimulation groups. Mean procedure duration was significantly shorter in the LV stimulation group (48.4 ± 16.9 min vs. 55.6 ± 26.9 min; p = 0.0013), with a difference of -0.12 (95% confidence interval: -0.20 to -0.05) in the log-transformed procedure duration (p = 0.0012). Effective stimulation was similar in the LV and RV stimulation groups: 124 (84.9%) versus 128 (87.1%) (p = 0.60). Safety of stimulation was also similar in the LV and RV stimulation groups: procedural success occurred in 151 (100%) versus 151 (99.3%) patients (p = 0.99); 30-day MACE-TAVR (major adverse cardiovascular event-transcatheter aortic valve replacement) occurred in 21 (13.9%) versus 26 (17.1%) patients (p = 0.44); fluoroscopy time (min) was lower in the LV stimulation group (13.48 ± 5.98 vs. 14.60 ± 5.59; p = 0.02), as was cost (€18,807 ± 1,318 vs. €19,437 ± 2,318; p = 0.001). CONCLUSIONS: Compared with RV stimulation, LV stimulation during TAVR was associated with significantly reduced procedure duration, fluoroscopy time, and cost, with similar efficacy and safety. (Direct Left Ventricular Rapid Pacing Via the Valve Delivery Guide-wire in TAVR [EASY TAVI]; NCT02781896).
Authors: Florence Leclercq; Pierre Alain Meunier; Thomas Gandet; Jean-Christophe Macia; Delphine Delseny; Philippe Gaudard; Marc Mourad; Laurent Schmutz; Pierre Robert; François Roubille; Guillaume Cayla; Mariama Akodad Journal: J Clin Med Date: 2022-05-16 Impact factor: 4.964
Authors: Henri Lu; David Rotzinger; Pierre Monney; Olivier Muller; Michael Egea; Matthieu Grange; Eric Eeckhout; Matthias Kirsch; Salah D Qanadli Journal: Front Cardiovasc Med Date: 2022-02-07
Authors: Viktor Kočka; Markéta Nováčková; Lenka Kratochvílová; Andrea Širáková; Jakub Sulženko; Tomáš Buděšínský; Marian Bystroń; Marek Neuberg; Petr Mašek; František Bednář; Michael Stern; And Petr Toušek Journal: Eur Heart J Suppl Date: 2022-03-30 Impact factor: 1.624
Authors: Thijmen W Hokken; Marjo de Ronde; Quinten Wolff; Thom Schermers; Joris F Ooms; Maarten P van Wiechen; Isabella Kardys; Joost Daemen; Peter P de Jaegere; Nicolas M Van Mieghem Journal: Catheter Cardiovasc Interv Date: 2021-11-27 Impact factor: 2.585